Pharmacist holding prescription The new complaint focuses on common, generic ointments used to treat a variety of skin conditions such as eczema, psoriasis and inflammation. (Photo: Shutterstock)

(Bloomberg) –Novartis AG’s Sandoz unit was at the center of a sweeping conspiracy with competitors to raise prices of generic drugs by more than 1,000%, according to the latest U.S. lawsuit by state antitrust enforcers against the industry.

A nationwide group of state attorneys general said in a complaint filed in federal court Wednesday that Sandoz and other drugmakers colluded to artificially inflate prices for more than 80 topical treatments like creams and ointments from 2009 through 2016.

 

BenefitsPRO

Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join BenefitsPRO.com now!

  • Unlimited access to BenefitsPRO.com - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
  • Exclusive discounts on BenefitsPRO.com and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2022 ALM Global, LLC. All Rights Reserved.